Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study.
Identifieur interne : 001D01 ( Ncbi/Checkpoint ); précédent : 001D00; suivant : 001D02Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study.
Auteurs : Roberta Zangaglia [Italie] ; Emilia Martignoni ; Margaret Glorioso ; Maria Ossola ; Giulio Riboldazzi ; Daniela Calandrella ; Gabriele Brunetti ; Claudio PacchettiSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2007.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Polyethylene Glycols, Surface-Active Agents.
- complications : Parkinson Disease.
- drug therapy : Constipation.
- etiology : Constipation.
- Aged, Chi-Square Distribution, Double-Blind Method, Female, Humans, Male, Severity of Illness Index, Time Factors.
Abstract
Chronic constipation is the most frequent symptom of autonomic system involvement in Parkinson's disease (PD). Quite often the symptom is severe and impairs patients' quality of life. The objective of this study is to determine the efficacy and safety of an isosmotic macrogol solution for the treatment of constipation in PD patients, in a double-blind, placebo-controlled study. A total of 57 PD patients with constipation were randomly assigned to receive an isosmotic macrogol electrolyte solution (MC-ES; 29 patients) or placebo (28 patients) for 8 weeks. Treatment efficacy was defined as complete relief of the symptom or a marked improvement of two of the following indicators: stool frequency, straining, stool consistency, use of rectal laxatives as a rescue therapy. The responder rates were significantly higher in the MC-ES group both at the first (4 weeks; P < 0.0003) and at the final evaluation (8 weeks; P < 0.0012). The frequency of bowel movements (P < 0.002) and stool consistency (P < 0.006) were significantly changed in the MC-ES group compared to the placebo group. At the final evaluation, a rectal laxative was used by 2 (12.5%) patients on placebo, whereas no use was recorded in the MC-ES group. Responder rate for straining showed a favorable trend in patients treated with macrogol versus placebo. Unified Parkinson's Disease Rating Scale Part III and Parkinson's Disease Questionnaire (PDQ-39) did not show any significant modification in either group during the 8-week treatment period. The results of this placebo-controlled study show the efficacy of MC-ES in the treatment of constipation in PD. MC-ES was well-tolerated and did not affect the course of PD.
DOI: 10.1002/mds.21243
PubMed: 17566120
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002638
- to stream PubMed, to step Curation: 002638
- to stream PubMed, to step Checkpoint: 002730
- to stream Ncbi, to step Merge: 001D01
- to stream Ncbi, to step Curation: 001D01
Links to Exploration step
pubmed:17566120Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study.</title><author><name sortKey="Zangaglia, Roberta" sort="Zangaglia, Roberta" uniqKey="Zangaglia R" first="Roberta" last="Zangaglia">Roberta Zangaglia</name><affiliation wicri:level="1"><nlm:affiliation>Parkinson's Disease and Movement Disorders Unit, IRCCS C. Mondino Institute of Neurology Foundation, Pavia, Italy. centro.parkinson@mondino.it</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Unit, IRCCS C. Mondino Institute of Neurology Foundation, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Martignoni, Emilia" sort="Martignoni, Emilia" uniqKey="Martignoni E" first="Emilia" last="Martignoni">Emilia Martignoni</name></author><author><name sortKey="Glorioso, Margaret" sort="Glorioso, Margaret" uniqKey="Glorioso M" first="Margaret" last="Glorioso">Margaret Glorioso</name></author><author><name sortKey="Ossola, Maria" sort="Ossola, Maria" uniqKey="Ossola M" first="Maria" last="Ossola">Maria Ossola</name></author><author><name sortKey="Riboldazzi, Giulio" sort="Riboldazzi, Giulio" uniqKey="Riboldazzi G" first="Giulio" last="Riboldazzi">Giulio Riboldazzi</name></author><author><name sortKey="Calandrella, Daniela" sort="Calandrella, Daniela" uniqKey="Calandrella D" first="Daniela" last="Calandrella">Daniela Calandrella</name></author><author><name sortKey="Brunetti, Gabriele" sort="Brunetti, Gabriele" uniqKey="Brunetti G" first="Gabriele" last="Brunetti">Gabriele Brunetti</name></author><author><name sortKey="Pacchetti, Claudio" sort="Pacchetti, Claudio" uniqKey="Pacchetti C" first="Claudio" last="Pacchetti">Claudio Pacchetti</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1002/mds.21243</idno><idno type="RBID">pubmed:17566120</idno><idno type="pmid">17566120</idno><idno type="wicri:Area/PubMed/Corpus">002638</idno><idno type="wicri:Area/PubMed/Curation">002638</idno><idno type="wicri:Area/PubMed/Checkpoint">002730</idno><idno type="wicri:Area/Ncbi/Merge">001D01</idno><idno type="wicri:Area/Ncbi/Curation">001D01</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D01</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study.</title><author><name sortKey="Zangaglia, Roberta" sort="Zangaglia, Roberta" uniqKey="Zangaglia R" first="Roberta" last="Zangaglia">Roberta Zangaglia</name><affiliation wicri:level="1"><nlm:affiliation>Parkinson's Disease and Movement Disorders Unit, IRCCS C. Mondino Institute of Neurology Foundation, Pavia, Italy. centro.parkinson@mondino.it</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Unit, IRCCS C. Mondino Institute of Neurology Foundation, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Martignoni, Emilia" sort="Martignoni, Emilia" uniqKey="Martignoni E" first="Emilia" last="Martignoni">Emilia Martignoni</name></author><author><name sortKey="Glorioso, Margaret" sort="Glorioso, Margaret" uniqKey="Glorioso M" first="Margaret" last="Glorioso">Margaret Glorioso</name></author><author><name sortKey="Ossola, Maria" sort="Ossola, Maria" uniqKey="Ossola M" first="Maria" last="Ossola">Maria Ossola</name></author><author><name sortKey="Riboldazzi, Giulio" sort="Riboldazzi, Giulio" uniqKey="Riboldazzi G" first="Giulio" last="Riboldazzi">Giulio Riboldazzi</name></author><author><name sortKey="Calandrella, Daniela" sort="Calandrella, Daniela" uniqKey="Calandrella D" first="Daniela" last="Calandrella">Daniela Calandrella</name></author><author><name sortKey="Brunetti, Gabriele" sort="Brunetti, Gabriele" uniqKey="Brunetti G" first="Gabriele" last="Brunetti">Gabriele Brunetti</name></author><author><name sortKey="Pacchetti, Claudio" sort="Pacchetti, Claudio" uniqKey="Pacchetti C" first="Claudio" last="Pacchetti">Claudio Pacchetti</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Chi-Square Distribution</term><term>Constipation (drug therapy)</term><term>Constipation (etiology)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Parkinson Disease (complications)</term><term>Polyethylene Glycols (therapeutic use)</term><term>Severity of Illness Index</term><term>Surface-Active Agents (therapeutic use)</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Polyethylene Glycols</term><term>Surface-Active Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Constipation</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Constipation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Chi-Square Distribution</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Severity of Illness Index</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Chronic constipation is the most frequent symptom of autonomic system involvement in Parkinson's disease (PD). Quite often the symptom is severe and impairs patients' quality of life. The objective of this study is to determine the efficacy and safety of an isosmotic macrogol solution for the treatment of constipation in PD patients, in a double-blind, placebo-controlled study. A total of 57 PD patients with constipation were randomly assigned to receive an isosmotic macrogol electrolyte solution (MC-ES; 29 patients) or placebo (28 patients) for 8 weeks. Treatment efficacy was defined as complete relief of the symptom or a marked improvement of two of the following indicators: stool frequency, straining, stool consistency, use of rectal laxatives as a rescue therapy. The responder rates were significantly higher in the MC-ES group both at the first (4 weeks; P < 0.0003) and at the final evaluation (8 weeks; P < 0.0012). The frequency of bowel movements (P < 0.002) and stool consistency (P < 0.006) were significantly changed in the MC-ES group compared to the placebo group. At the final evaluation, a rectal laxative was used by 2 (12.5%) patients on placebo, whereas no use was recorded in the MC-ES group. Responder rate for straining showed a favorable trend in patients treated with macrogol versus placebo. Unified Parkinson's Disease Rating Scale Part III and Parkinson's Disease Questionnaire (PDQ-39) did not show any significant modification in either group during the 8-week treatment period. The results of this placebo-controlled study show the efficacy of MC-ES in the treatment of constipation in PD. MC-ES was well-tolerated and did not affect the course of PD.</div></front></TEI><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="Brunetti, Gabriele" sort="Brunetti, Gabriele" uniqKey="Brunetti G" first="Gabriele" last="Brunetti">Gabriele Brunetti</name><name sortKey="Calandrella, Daniela" sort="Calandrella, Daniela" uniqKey="Calandrella D" first="Daniela" last="Calandrella">Daniela Calandrella</name><name sortKey="Glorioso, Margaret" sort="Glorioso, Margaret" uniqKey="Glorioso M" first="Margaret" last="Glorioso">Margaret Glorioso</name><name sortKey="Martignoni, Emilia" sort="Martignoni, Emilia" uniqKey="Martignoni E" first="Emilia" last="Martignoni">Emilia Martignoni</name><name sortKey="Ossola, Maria" sort="Ossola, Maria" uniqKey="Ossola M" first="Maria" last="Ossola">Maria Ossola</name><name sortKey="Pacchetti, Claudio" sort="Pacchetti, Claudio" uniqKey="Pacchetti C" first="Claudio" last="Pacchetti">Claudio Pacchetti</name><name sortKey="Riboldazzi, Giulio" sort="Riboldazzi, Giulio" uniqKey="Riboldazzi G" first="Giulio" last="Riboldazzi">Giulio Riboldazzi</name></noCountry><country name="Italie"><noRegion><name sortKey="Zangaglia, Roberta" sort="Zangaglia, Roberta" uniqKey="Zangaglia R" first="Roberta" last="Zangaglia">Roberta Zangaglia</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D01 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001D01 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:17566120
|texte= Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:17566120" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |